Paper42036664
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.
Lu N and 3 others. J Hematol Oncol, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming. Papers, record 42036664. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42036664
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Immunoconjugates | Major topic |
| Breast Neoplasms | Major topic |
| Antineoplastic Agents, Immunological | Major topic |
| Humans | |
| Female | |
| Drug Delivery Systems | |
| Animals |
Source PubMed
References106
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39575243 | Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies. | Front Immunol | 2024 | https://conductscience.org/library/papers/39575243 | PubMed |
| 2 | 38153656 | Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions. | Arch Pharm Res | 2024 | https://conductscience.org/library/papers/38153656 | PubMed |
| 3 | 33408395 | Method of the Year: spatially resolved transcriptomics. | Nat Methods | 2021 | https://conductscience.org/library/papers/33408395 | PubMed |
| 4 | 31825192 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31825192 | PubMed |
| 5 | 31548545 | Breast cancer. | Nat Rev Dis Primers | 2019 | https://conductscience.org/library/papers/31548545 | PubMed |
| 6 | 40175391 | Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). | Nat Commun | 2025 | https://conductscience.org/library/papers/40175391 | PubMed |
| 7 | 38614094 | A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38614094 | PubMed |
| 8 | 30664738 | Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. | Nat Immunol | 2019 | https://conductscience.org/library/papers/30664738 | PubMed |
| 9 | 39376738 | Next-generation spatial transcriptomics: unleashing the power to gear up translational oncology. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39376738 | PubMed |
| 10 | 36495879 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/36495879 | PubMed |
| 11 | 24667376 | Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. | Sci Signal | 2014 | https://conductscience.org/library/papers/24667376 | PubMed |
| 12 | 39786401 | OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. | Mol Cancer Ther | 2025 | https://conductscience.org/library/papers/39786401 | PubMed |
| 13 | 38951909 | A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance. | Breast Cancer Res | 2024 | https://conductscience.org/library/papers/38951909 | PubMed |
| 14 | 28480899 | Immunosuppressive cell death in cancer. | Nat Rev Immunol | 2017 | https://conductscience.org/library/papers/28480899 | PubMed |
| 15 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 16 | 15864276 | ERBB receptors and cancer: the complexity of targeted inhibitors. | Nat Rev Cancer | 2005 | https://conductscience.org/library/papers/15864276 | PubMed |
| 17 | 40460679 | The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. | ESMO Open | 2025 | https://conductscience.org/library/papers/40460679 | PubMed |
| 18 | 34782633 | A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. | Sci Rep | 2021 | https://conductscience.org/library/papers/34782633 | PubMed |
| 19 | 41280925 | The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data. | Front Immunol | 2025 | https://conductscience.org/library/papers/41280925 | PubMed |
| 20 | 40364727 | A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40364727 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42711696 | Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42711696 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AZIN2 | 113451 | PubTator's text mining | https://conductscience.org/library/genes/113451 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ERBB3 | 2065 | PubTator's text mining | https://conductscience.org/library/genes/2065 | NCBI Gene |
| TACSTD2 | 4070 | PubTator's text mining | https://conductscience.org/library/genes/4070 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42036664
GET https://conductscience.org/api/papers/v1/42036664/references?page=2